- Home
- RPRX vs ACM Comparison
RPRX vs ACM Comparison
Compare RPRX & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- ACM
- Stock Information
- Founded
- RPRX 1996
- ACM 1980
- Country
- RPRX United States
- ACM United States
- Employees
- RPRX N/A
- ACM N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- ACM Military/Government/Technical
- Sector
- RPRX Health Care
- ACM Consumer Discretionary
- Exchange
- RPRX Nasdaq
- ACM Nasdaq
- Market Cap
- RPRX 15.6B
- ACM 16.3B
- IPO Year
- RPRX 2020
- ACM 2007
- Fundamental
- Price
- RPRX $35.87
- ACM $124.89
- Analyst Decision
- RPRX Strong Buy
- ACM Strong Buy
- Analyst Count
- RPRX 3
- ACM 10
- Target Price
- RPRX $45.33
- ACM $128.50
- AVG Volume (30 Days)
- RPRX 3.1M
- ACM 830.2K
- Earning Date
- RPRX 08-06-2025
- ACM 08-04-2025
- Dividend Yield
- RPRX 2.45%
- ACM 0.83%
- EPS Growth
- RPRX 54.86
- ACM 147.22
- EPS
- RPRX 2.32
- ACM 4.59
- Revenue
- RPRX $2,305,243,000.00
- ACM $16,074,699,000.00
- Revenue This Year
- RPRX $33.77
- ACM $2.09
- Revenue Next Year
- RPRX $4.62
- ACM $5.76
- P/E Ratio
- RPRX $15.45
- ACM $27.21
- Revenue Growth
- RPRX 3.02
- ACM 1.50
- 52 Week Low
- RPRX $24.05
- ACM $85.00
- 52 Week High
- RPRX $38.00
- ACM $126.29
- Technical
- Relative Strength Index (RSI)
- RPRX 42.45
- ACM 69.11
- Support Level
- RPRX $35.48
- ACM $122.49
- Resistance Level
- RPRX $36.99
- ACM $126.29
- Average True Range (ATR)
- RPRX 0.68
- ACM 1.98
- MACD
- RPRX -0.14
- ACM 0.34
- Stochastic Oscillator
- RPRX 7.28
- ACM 81.72
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.